Navigation Links
PDL BioPharma Announces Third Quarter 2011 Financial Results
Date:11/9/2011

INCLINE VILLAGE, Nev., Nov. 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2011.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

RevenuesTotal revenues for the third quarter of 2011 were $83.8 million, compared to $86.4 million for the same period of 2010, a three percent year-over-year decrease. Total revenues for the nine months ended September 30, 2011, were $289.2 million, compared to $268.8 million for the same period of 2010, an eight percent increase.

The third quarter 2011 revenue decline is driven primarily by reduced royalties from second quarter 2011 sales of Avastin® partially offset by increased royalties from second quarter 2011 sales of Herceptin®, Lucentis® and Tysabri®. Also contributing to the decline is a lower average royalty rate on sales of Avastin, Herceptin, Lucentis and Xolair® (the Genentech Products) that are either made or sold in the United States (U.S.-based Sales) due to higher year-to-date sales in 2011. Sales of the Genentech Products are subject to a tiered royalty rate for U.S.-based Sales and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States. Due to the tiering, in the second quarter of 2011, only 15% of U.S.-based Sales were above the lowest royalty rate of one percent as compared with 45% of U.S.-based Sales for the second quarter 2010. The net sales thresholds and the applicable royalty rates for product that is either made or sold in the United States are outlined below:   Royalty RateNet sales up to $1.5 billion

3.0%Net sales between $1.5 billion and $2.5 billion

2.5%Net sales between $2.5 billion and $4.0 billion

2.0%Net sales e
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
3. PDL BioPharma to Announce Third Quarter 2011 Financial Results on November 9, 2011
4. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
5. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
6. Sentry BioPharma Services Earns a GSA Federal Supply Schedule Contract #GS-10F-0432X
7. Genesis Biopharma Signs Worldwide License Agreement with the NIH for Adoptive Cell Therapy to Treat a Variety of Cancers
8. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
9. CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan
10. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
11. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "China Orthopedic Instrument Industry Report, 2014-2017" report ... aging population and rising proportion of reimbursement for medical ... effectively released, with its scale presenting a CAGR of ... products are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... According to a new ... type (SFE, Cold Pressed, Organic Solvent, & Others), and ... Fragrance, & Others) - Global Trends & Forecast ... the Amaranth Seed Oil Market with an analysis ... of value. The Amaranth Seed Oil Market size ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2
... Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, ... of Treatment , , SAN DIEGO, June ... its Phase 2 clinical trial evaluating the safety and ... the treatment of severe complicated skin and skin structure ...
... sets to be released-- , , PARIS, ... in patients with blepharospasm and cervical dystonia -- one placebo-controlled ... presented at the Movement Disorder Society (MDS) 13th annual International ... Pharmaceuticals, which plans to file a Biologic License Application (BLA) ...
Cached Medicine Technology:Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 2Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 3Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 4Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:8/29/2014)... cancer patients lacking knowledge about the disease have difficulty ... quality of care and long-term results, new research suggests. ... age of 63. All were newly diagnosed with localized ... associated with greater difficulty deciding which treatment to choose ... the study found. "For prostate cancer, there is ...
(Date:8/29/2014)... Washington University School of Medicine have identified one way ... important insight that could lead to new therapies, in ... Cell Host & Microbe . , In work performed ... Source, the researchers developed a detailed map of how ... protein that takes signaling molecules in and out of ...
(Date:8/29/2014)... August 29, 2014 After having a ... Pa., had to have breast reconstruction. She found that ... so she decided that there needed to be a ... for a woman or man who needs or wants ... as promotes confidence and peace of mind. Producible in ...
(Date:8/29/2014)... August 29, 2014 Evolutions Medical & ... in the Santa Barbara News-Press Readers’ Choice 2014 poll. ... Readers’ Choice poll as Best Medical Spa. The 2014 ... the following about Evolutions Medical Spa recognition: , “Not ... is recognized as a top-notch, cutting-edge medical spa as ...
(Date:8/29/2014)... RBS Reputation Management has brought a new service ... is to help those individuals and organizations that are suffering ... The service would push down the ranking of Scam Book ... invisible on Google. , RBS Reputation Management provides guarantee ... how company can provide guarantee of results with the service, ...
Breaking Medicine News(10 mins):Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 3Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2
... , NEW YORK, Sept. 22 Reportlinker.com ... in its catalogue. , , ... and Healthcare Transaction Processing, 3rd Edition , The ... , , The North American market ...
... News media and scientists interested in finance, entrepreneurships and ... Chemical Society (ACS) Small & Medium Business Webinar on ... ) Small Business Innovation Research (SBIR) priority funding ... 24, 2 3 p.m. Eastern Time, the webinar ...
... think the air outside is polluted, a new research report ... ( http://www.genetics.org ) might make you to think twice ... show how about 3 percent of the air we breathe ... Specifically, these superoxides lead to the creation of a toxic ...
... BRYAN, Ohio, Sept. 22 For most ... more and more children are diagnosed with allergies and intolerances to ... leave many kids feeling left out. Spangler Candy Company ... inviting kids back in on all the fun. , , ...
... , MERRIAM, Kan., Sept. 22 ... . ." t-shirts to be auctioned off to benefit Christina ... National Denim Day on October 2, one of the largest single ... To view the Multimedia News Release, go to: ...
... CEDAR KNOLLS, N.J., Sept. 22 ScienceFirst is ... as a result of ScienceFirst,s sustained annual growth. , ... senior account director at ScienceFirst, where he will be ... delivery. Before joining ScienceFirst, Steen held the position of ...
Cached Medicine News:Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 2Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 3Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 4Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 5Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 6Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 7Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 8Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 9Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 10Health News:Reportlinker Adds North American Market for Third Party Payroll, Payment and Healthcare Transaction Processing, 3rd Edition , The Report 11Health News:New research provides new insight into age-related muscle decline 2Health News:Spangler Helps Children with Food Allergies and Intolerances Enjoy a Worry-Free Halloween 2Health News:Video: Celebrities Join Christina Applegate to Share Their Heart for Breast Cancer Awareness 2Health News:Video: Celebrities Join Christina Applegate to Share Their Heart for Breast Cancer Awareness 3Health News:Video: Celebrities Join Christina Applegate to Share Their Heart for Breast Cancer Awareness 4
... 25,000 units Penicillin/25,000 ... Cell Culture Reagent and ... in accordance with cGMP ... culture tested to assure ...
Penicillin-Streptomycin-Glutamine (100X) liquid...
Penicillin-Streptomycin liquid...
... combination of penicillin and streptomycin which ... and gram negative bacteria when used ... I.U. Penicillin/100,000 g/mL Streptomycin per liter. ... water at concentrations of 5,000 I.U. ...
Medicine Products: